![Gray W. Wood](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gray W. Wood
Fondateur chez
TVAX BIOM
Profil
Gray W.
Wood is the founder of TVAX Biomedical, Inc. (founded in 2011) and TVAX Biomedical I LLC (founded in 2004).
He holds the title of Chairman & Chief Scientific Officer at TVAX Biomedical, Inc. and Chairman, President & Chief Executive Officer at TVAX Biomedical I LLC.
Currently, Dr. Wood is the Director at ELIAS Animal Health LLC.
In the past, he worked as the Director-Cancer Immunotherapy Laboratory at Wayne State University (Michigan) and the University of Kansas.
Dr. Wood completed his undergraduate degree at Kalamazoo College and obtained a doctorate degree from the State University of New York at Buffalo.
Postes actifs de Gray W. Wood
| Sociétés | Poste | Début |
|---|---|---|
| TVAX BIOM | Fondateur | 14/07/2011 |
TVAX Biomedical I LLC
 TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. | Directeur Général | - |
ELIAS Animal Health LLC
 ELIAS Animal Health LLC Miscellaneous Commercial ServicesCommercial Services Operates as a medical biotechnology company that develops treatments for cancer in companion animals | Directeur/Membre du Conseil | - |
Anciens postes connus de Gray W. Wood
| Sociétés | Poste | Fin |
|---|---|---|
Wayne State University (Michigan)
 Wayne State University (Michigan) Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formation de Gray W. Wood
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
18
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
TVAX Biomedical, Inc.
 TVAX Biomedical, Inc. BiotechnologyHealth Technology Manufactures and sells healthcare products | Health Technology |
ELIAS Animal Health LLC
ELIAS Animal Health LLC Miscellaneous Commercial ServicesCommercial Services Operates as a medical biotechnology company that develops treatments for cancer in companion animals | Commercial Services |
Wayne State University (Michigan)
Wayne State University (Michigan) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kalamazoo College
 Kalamazoo College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
State University of New York at Buffalo
 State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Kansas
University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TVAX Biomedical I LLC
TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. |
